Autolus, Moderna ink license agreement

By The Science Advisory Board staff writers

August 2, 2021 -- Biopharmaceutical company Autolus Therapeutics has granted Moderna exclusive license to develop and market mRNA therapeutics that include Autolus' binding agents for four immuno-oncology targets.

Under terms of the deal, Autolus will be eligible to receive payment for each target Moderna licenses, as well as to receive milestone payments for each target that is successfully brought to market. Autolus will also receive royalties on net sales of each target.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.